UK markets closed

Kala Pharmaceuticals, Inc. (KALA)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
6.30+0.11 (+1.78%)
At close: 04:00PM EDT
6.75 +0.45 (+7.14%)
After hours: 06:10PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 17.74M
Enterprise value 3.17M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)2.36
Enterprise value/revenue -15.67
Enterprise value/EBITDA -0.09

Trading information

Stock price history

Beta (5Y monthly) -1.84
52-week change 3-58.98%
S&P500 52-week change 322.36%
52-week high 319.35
52-week low 35.10
50-day moving average 37.36
200-day moving average 38.82

Share statistics

Avg vol (3-month) 319.86k
Avg vol (10-day) 310.65k
Shares outstanding 52.82M
Implied shares outstanding 62.82M
Float 82.31M
% held by insiders 117.95%
% held by institutions 122.73%
Shares short (15 Apr 2024) 45.05k
Short ratio (15 Apr 2024) 40.33
Short % of float (15 Apr 2024) 40.19%
Short % of shares outstanding (15 Apr 2024) 40.18%
Shares short (prior month 15 Mar 2024) 412.07k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:50
Last split date 321 Oct 2022

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-34.28%
Return on equity (ttm)-318.75%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -38.85M
Net income avi to common (ttm)-42.2M
Diluted EPS (ttm)-17.35
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)50.9M
Total cash per share (mrq)18.07
Total debt (mrq)36.32M
Total debt/equity (mrq)484.05%
Current ratio (mrq)6.34
Book value per share (mrq)2.72

Cash flow statement

Operating cash flow (ttm)-27.93M
Levered free cash flow (ttm)-18.88M